News

In a new paper, researchers announce what they believe is a major step forward for CRISPR: An efficient, multi-purpose, mini CRISPR system. Whereas the commonly used CRISPR systems – with names like Cas9 and Cas12a denoting various versions of CRISPR-associated (Cas) proteins – are made of about 1000 to 1500 amino acids, their “CasMINI” has 529.

Researchers have combined the health records of over six million patients and found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.

Researchers from the University of Oxford and the Ludwig Institute for Cancer Research are harnessing the viral vector technology used to create the Oxford–AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.

A new computational approach may predict how individual patients are likely to respond to vaccines. In the future, it could lead to new design principles for vaccines that take an individual’s personalized characteristics into account.

Vaccinations against human papillomavirus (HPV) are expected to yield significant reductions in the rates of throat and mouth cancers in the U.S., but will not do so until after 2045, according to a new modeling study.

The UK and Australia will share COVID-19 vaccine doses to benefit each other’s life-saving vaccine rollout programs.

Researchers have discovered a novel mechanism showing how a certain gene mutation allows tumors to evade detection by the immune system in colorectal cancer patients.

A new study from Penn Medicine shows that CAR T cells expressing a naturally occurring RNA called RN7SL1 can activate the body’s immune cells against difficult-to-treat cancers.

Researchers attempting to develop rheumatoid arthritis therapies with minimal side effects have genetically engineered cells that deliver a biologic drug in response to inflammation.

Researchers at King’s College London analysed data from participants logging their symptoms, tests and vaccines on the UK ZOE COVID Symptom Study app between 8th December 2020 and 4 July 2021, including 1,240,009 (first dose) and 971,504 (second dose) vaccinated UK adults.